Results 131 to 140 of about 9,994 (168)

Clinical Pharmacokinetics of Galantamine

Clinical Pharmacokinetics, 2003
Galantamine is the most recently approved cholinergic drug for the treatment of Alzheimer's disease, the most common type of dementia. Vascular dementia and Alzheimer's disease with cerebrovascular disease are also common in older patients. Dementia affects cognition, causes losses in ability to perform activities of daily living and often results in ...
openaire   +2 more sources

Galantamine

2023
openaire   +1 more source

Galantamine hydrobromide

American Journal of Health-System Pharmacy, 2001
openaire   +2 more sources

Galantamine

2010
Husseini K. Manji, Jorge Quiroz, R. Andrew Chambers, Anthony Absalom, David Menon, Patrizia Porcu, A. Leslie Morrow, Wolfgang Fleischhacker, Naheed (Max) Mirza, Christine A. Franco, Marc N. Potenza, Robert Kessler, Ronald L. Cowan, Daniel Hoyer, Eric J. Nestler, Elizabath C. Warburton, Anthony Absalom, David Menon, David S. Baldwin, Sophie Tambour, John C. Crabbe, Nicole Edgar, Etienne Sibille, Linda Lundstroem, Silvia Gatti McArthur, Will Spooren, R. H. de Rijk, E. R. De Kloet, Michael J. Owens, Chase H. Bourke, Joachim D. Uys, Peter W. Kalivas, Linda Lundstroem, Silvia Gatti McArthur, Will Spooren, Anne M. Andrews, Greg A. Gerhardt, Lynette Daws, Barbara J. Mason, Charles J. Heyser, Seiya Miyamoto, Peter Riederer, Siegfried Hoyer, Suzanne H. Mitchell, Harriet de Wit, Matthew I. Palmatier, Rick A. Bevins, Jill B. Becker, C. Neill Epperson, Gorkem Yararbas, Sakire Pogun, Michael M. Morgan, MacDonald J. Christie, Michael M. Morgan, MacDonald J. Christie, Ben J. Harrison, Christos Pantelis, Seiya Miyamoto, Andrew Young   +58 more
openaire   +1 more source

Galantamine

2021
openaire   +1 more source

Galantamine Nanoparticles Outperform Oral Galantamine in An Alzheimer’S Rat Model: Pharmacokinetics and Pharmacodynamics

Nanomedicine, 2021
Ragwa M Farid, Amira Sayed Hanafy, Samar O El-Ganainy   +2 more
exaly  

Galantamine

Reactions Weekly, 2015
openaire   +2 more sources

Galantamine for Alzheimer's disease

Expert Opinion on Drug Metabolism and Toxicology, 2010
Harald Hampel, Johannes Pantel
exaly  

An update on the pharmacology of galantamine

Expert Opinion on Investigational Drugs, 2007
Antonio Garcia Garcia, JOSÉ Marco-Contelles, Manuela Garcia Lopez   +2 more
exaly  

Galantamine inhibits β-amyloid aggregation and cytotoxicity

Journal of the Neurological Sciences, 2009
Richard Bramwell Parsons, David Allsop
exaly